IDH1 and glioblastoma: Standard post-surgical administration of TMZ monotherapy with concomitant XRT is moderately effective as DNA damaging therapy for IDH-WT GBM ( ~ 2-month survival benefit) [2, 41] over XRT alone, but in most cases does not result in a durable response.